Page last updated: 2024-09-03

pd 128907 and butaclamol

pd 128907 has been researched along with butaclamol in 1 studies

Compound Research Comparison

Studies
(pd 128907)
Trials
(pd 128907)
Recent Studies (post-2010)
(pd 128907)
Studies
(butaclamol)
Trials
(butaclamol)
Recent Studies (post-2010) (butaclamol)
90445016

Protein Interaction Comparison

ProteinTaxonomypd 128907 (IC50)butaclamol (IC50)
D(2) dopamine receptorHomo sapiens (human)0.0023
DRattus norvegicus (Norway rat)0.0053
D(3) dopamine receptorRattus norvegicus (Norway rat)0.0053
D(1B) dopamine receptorRattus norvegicus (Norway rat)0.0053
D(4) dopamine receptorRattus norvegicus (Norway rat)0.0053
D(3) dopamine receptorHomo sapiens (human)0.0112
D(2) dopamine receptorRattus norvegicus (Norway rat)0.0034

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Akunne, HC; Cooke, LW; Damsma, G; Davis, MD; Georgic, LM; MacKenzie, RG; Pugsley, TA; Shih, YH; Whetzel, SZ; Wikstrom, H1

Other Studies

1 other study(ies) available for pd 128907 and butaclamol

ArticleYear
Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    The Journal of pharmacology and experimental therapeutics, 1995, Volume: 275, Issue:3

    Topics: Animals; Behavior, Animal; Benzopyrans; Brain; CHO Cells; Cricetinae; Dopamine Agonists; Humans; Male; Mice; Mitosis; Oxazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Saimiri; Spiperone

1995